Abstract:Background: Current hypertension guidelines recommend combination of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker with a calcium-channel blocker or thiazide diuretic as initial antihypertensive therapy in patients with monotherapy uncontrolled hypertension. However, to what extent these two different combinations are comparable in blood pressure (BP)-lowering efficacy and safety remains under investigation, especially in the Chinese population. We investigated the BP-lowering efficacy and safety of the amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies in Chinese patients. Methods: In a multi-center, randomized, actively controlled, parallel-group trial, we enrolled patients with stage 1 or 2 hypertension from July 2018 to June 2021 in 20 hospitals and community health centers across China. Of the 894 screened patients, 560 eligible patients were randomly assigned to amlodipine/benazepril 5/10 mg (n = 282) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 278), with 213 and 212 patients, respectively, who completed the study and had a valid repeat ambulatory BP recording during follow-up and were included in the efficacy analysis. The primary outcome was the change from baseline to 24 weeks of treatment in 24-h ambulatory systolic BP. Adverse events including symptoms and clinically significant changes in physical examinations and laboratory findings were recorded for safety analysis. Results: In the efficacy analysis (n = 425), the primary outcome, 24-h ambulatory systolic BP reduction, was - 13.8 ± 1.2 mmHg in the amlodipine/benazepril group and - 12.3 ± 1.2 mmHg in the benazepril/hydrochlorothiazide group, with a between-group difference of - 1.51 (p = 0.36) mmHg. The between-group differences for major secondary outcomes were - 1.47 (p = 0.18) in 24-h diastolic BP, - 2.86 (p = 0.13) and - 2.74 (p = 0.03) in daytime systolic and diastolic BP, and - 0.45 (p = 0.82) and - 0.93 (p = 0.44) in nighttime systolic and diastolic BP. In the safety analysis (n = 560), the incidence rate of dry cough was significantly lower in the amlodipine/benazepril group than in the benazepril/hydrochlorothiazide group (5.3% vs 10.1%, p = 0.04). Conclusions: The amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies were comparable in ambulatory systolic BP lowering. The former combination, compared with the latter, had a greater BP-lowering effect in the daytime and a lower incidence rate of dry cough. Trial registration: ClinicalTrials.gov, NCT03682692. Registered on 18 September 2018.

Comparison of the Efficacy and Tolerance of Moxonidine with Enalapril in Mild to Moderate Essential Hypertension

Evaluation of Efficacy of Atenolol and Diltiazem-Sr in the Treatment of Hypertension

Efficacy Comparison Between 5 Mg Perindopril Arginine Salt and 4 Mg Perindopril Tert-Butylamine Salt for Patients with Mild to Moderate Essential Hypertension

Effects of Atenolol and Diltiazem-Sr on Quality of Life in the Hypertensive Patients

Multicentre Clinical Trial on Moxonidine Hydrochloride for Treatment of Hypertension

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

Efficacy and Safety of Torasemide in Patients with Mild to Moderate Essential Hypertension

Comparison of Cilazapril or Enalapril in Treatment of Patients with Essential Hypertension

Clinical Observation on Hypotensive and Left Ventricular Hypertrophy-Reversing Effects by Moxonidine

Efficacy of Losartan versus Enalapril in Treatment of Mild and Moderate Hypertension

Evaluation of short-term efficacy of enalapril in middle aged and older patients with mild to moderate essential hypertension in rural communities in Anqing and Lianyungang

Comparative Effect of Felodipine and Enalapril in Hypertension

Comparison of efficacy and tolerability of felodipine ER monotherapy and combined felodipine ER and losartan in patients with essential hypertension

The Efficacy and Safety of Amlodipine Maleate on Patients with Mild to Moderate Essential Hypertension

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

A Comparison of Initial Treatment with Losartan/hctz Versus Losartan Monotherapy in Chinese Patients with Mild to Moderate Essential Hypertension.

MARRIAGE: A Randomized Trial of Moxonidine Versus Ramipril or in Combination With Ramipril in Overweight Patients With Hypertension and Impaired Fasting Glucose or Diabetes Mellitus. Impact on Blood Pressure, Heart Rate and Metabolic Parameters

The Efficacy of Nebivolol on Patient with Mild or Moderate Mssential Hypertension by Different Smbulatory Blood Pressure Monitoring Methods

Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial

Double Blind Randomized Multicenter Clinical Study on Doxazosin Mesylate for Treatment of Hypertension

Using Different Methods to Evaluate the Efficacy of Olmesartan Medoxomil in Chinese Patients with Mild to Moderate Essential Hypertension According to Ambulatory Blood Pressure Monitoring